Trial reportNeurologia medico-chirurgica2025
Preliminary Safety Study of a Single-dose Perampanel Drip Infusion in Brain Tumor Patients to Prevent Early Postoperative Seizures: The poSTOP Seizure-1 SF Study.
Trial report in Neurologia medico-chirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early postoperative seizures, defined as occurring within 7 days after surgery, are a significant complication that occurs following neurosurgical procedures involving cerebral manipulation. As a result, short-term antiseizure medication is typically administered in Japan despite the lack of consensus regarding its prophylactic use. Perampanel hydrate, an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, was recently introduced in an intravenous formulation in Japan, providing new potential for early postoperative seizures prevention during the perioperative period. This study aimed to evaluate the safety and feasibility of a single-dose intravenous infusion of perampanel hydrate during brain tumor surgery. We conducted a single-arm, open-label, exploratory safety trial involving 10 adult patients undergoing brain tumor resection. Each participant received a 6 mg intravenous dose of perampanel hydrate during surgery, with no additional antiseizure medication administered postoperatively unless clinically indicated. The primary endpoint was the incidence of grade 3 or higher adverse events related to the study drug. Secondary endpoints included hematological toxicity, the incidence of early postoperative seizures, anesthetic recovery time, and perampanel hydrate blood concentration profiles. No grade 3 or higher adverse events were observed. Minor adverse events included transient grade 2 liver enzyme elevations and postoperative restlessness, both of which resolved within a week. Notably, no cases of early postoperative seizures occurred, and perampanel hydrate blood levels remained high even 7 days after a single administration. Intravenous perampanel hydrate appears safe and well tolerated in the perioperative setting and may effectively prevent early postoperative seizures. Further studies are planned to evaluate its efficacy in larger patient cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.